<DOC>
	<DOCNO>NCT02201316</DOCNO>
	<brief_summary>This study aim determine relative bioavailability two candidate formulation mosapride citrate 5mg tablet compare reference product GASMOTIN ( mosapride citrate 5mg ) Dainippon Pharmaceutical Company healthy adult subject . This open-label , randomise , single dose , three-way crossover , six sequence study . Subjects receive single oral dose separate least 7 day great 14 day washout period . This study require select candidate mosapride citrate ( GR107719B ) formulation development provide data allow design future pivotal bioequivalence study . The candidate formulation compare innovator GASMOTIN . GASMOTIN trademark Dainippon Sumitomo Pharmaceutical Company .</brief_summary>
	<brief_title>A Pilot Study Determine Relative Bioavailability Mosapride 5mg From Two Candidate Formulations GR107719B Relative One 5mg Tablet Reference Mosapride Citrate ( GASMOTINâ„¢ ) Healthy Adult Human Subjects Under Fasting Conditions</brief_title>
	<detailed_description />
	<mesh_term>Gastritis</mesh_term>
	<mesh_term>Mosapride</mesh_term>
	<mesh_term>Citric Acid</mesh_term>
	<criteria>Male female age 18 65 year age inclusive , time signing informed consent . Healthy determine responsible experienced physician , base medical evaluation include medical history , physical examination , laboratory test cardiac monitoring . A subject clinical abnormality laboratory parameter ( ) is/are specifically list inclusion exclusion criterion , outside reference range population study may include Investigator consultation GSK Medical Monitor require agree document find unlikely introduce additional risk factor interfere study procedure . Body weight &gt; = 50 kilogram ( kg ) body mass index within range 19 24.9 kg/m^2 ( inclusive ) . A female subject eligible participate : Nonchildbearing potential define premenopausal female document tubal ligation hysterectomy definition , `` document '' refers outcome investigator's/designee 's review subject 's medical history study eligibility , obtain via verbal interview subject subject 's medical record ; postmenopausal define 12 month spontaneous amenorrhea [ questionable case blood sample simultaneous follicle stimulate hormone ( FSH ) &gt; 40 milliinternational unit per milliliter ( MlU/mL ) estradiol &lt; 40 picograms per mililiter ( pg/mL ) [ &lt; 147 picomole per liter ] confirmatory ] . Females hormone replacement therapy ( HRT ) whose menopausal status doubt require use one contraception method wish continue HRT study . Otherwise , must discontinue HRT allow confirmation postmenopausal status prior study enrollment . For form HRT , least 24 week elapse cessation therapy blood draw ; interval depend type dosage HRT . Following confirmation postmenopausal status , resume use HRT study without use contraceptive method ; Childbearing potential negative pregnancy test determine serum human chorionic gonadotrophin ( hCG ) test screen prior dosing AND ; Agrees use one contraception method list protocol appropriate period time ( determined product label investigator ) prior start dose sufficiently minimize risk pregnancy point . Female subject must agree use contraception followup contact visit ; OR samesex partner , prefer usual lifestyle . Male subject female partner childbearing potential must agree use one contraception method list Protocol . This criterion must follow time first dose study medication followup contact visit . Capable give write informed consent , include compliance requirement restriction list consent form Alanine aminotransferase , alkaline phosphatase bilirubin &lt; =1.5x upper limit normal ( ULN ) ( isolated bilirubin &gt; 1.5xULN acceptable bilirubin fractionate direct bilirubin &lt; 35 % ) . Based single average correct QT interval ( QTc ) value triplicate electrocardiogram obtain brief recording period : QTcF &lt; 450 msec Current chronic history liver disease , know hepatic biliary abnormality ( exception Gilbert 's syndrome asymptomatic gallstone ) . History regular alcohol consumption within 6 month study define : An average weekly intake &gt; 21 unit male &gt; 14 unit female . One unit equivalent 8 gram alcohol : halfpint ( approximately 240 milliliter [ mL ] ) beer , 1 glass ( 100 mL ) wine 1 ( 25 mL ) measure spirit . History sensitivity heparin heparininduced thrombocytopenia . History sensitivity study medication , component thereof history drug allergy , opinion investigator GSK Medical Monitor , contraindicate participation . Gastrointestinal disease gastrointestinal surgical history affect absorption investigational product . A positive prestudy Hepatitis B surface antigen positive Hepatitis C antibody result within 3 month screen Urinary cotinine level indicative smoke history regular use tobacco nicotinecontaining product within 6 month prior screen . A positive prestudy drug/alcohol screen . A positive test Human Immunodeficiency Virus ( HIV ) antibody . Pregnant female determine positive serum hCG test screen prior dosing . Where participation study would result donation blood blood product excess 500 mL within 90 day period . Lactating female . The subject participate clinical trial receive investigational product within following time period prior first dose day current study : 90 day , 5 halflives twice duration biological effect investigational product ( whichever longer ) . Exposure four new chemical entity within 12 month prior first dose day .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>July 2014</verification_date>
	<keyword>Healthy adult human subject</keyword>
	<keyword>Mosapride citrate anhydrous</keyword>
	<keyword>Bioequivalence</keyword>
	<keyword>Dyspepsia</keyword>
</DOC>